Table 2.

In situ hybridization analysis of the expression of TACSTD2 and S100A2 in atypical adenomatous hyperplasia (AAH) and small‐sized adenocarcinoma of the lung

	No. cases	TACSTD2 (%)	S100A2 (%)
AAH	14	7 (50)	5 (36)
BAC (type A and B)	12	8 (67)	2 (17)
Mixed BAC (type C)	10	8 (80)	2 (20)
Non‐BAC (type D, E, F)	10	4 (40)	3 (30)
Total	46	27 (59)	12 (26)

TACSTD2, tumor‐associated calcium signal transducer 2; BAC, bronchioloalveolar carcinoma; mixed BAC, adenocarcinoma of mixed subtype with BAC component; non‐BAC, adenocarcinoma without BAC component; type A, B, C, D, E, and F, see definitions in Materials and Methods section. If more than 10% of tumor cells were strongly stained, this was taken as positive staining.